Progressive Pulmonary Fibrosis Ppf clinical trials

Explore recruiting progressive pulmonary fibrosis ppf clinical trials.

Recruiting progressive pulmonary fibrosis ppf studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Progressive Pulmonary Fibrosis Ppf trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis: The FIBRO-PET study.

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis: The FIBRO-PET study.

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough

Belgium, Czechia, Poland, Germany, Sweden, Spain +9 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)

France, Germany, Italy, Spain, Poland, Netherlands +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON)

Spain, Denmark, Slovenia, Croatia, Norway, Italy +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multinational, Long-Term, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [Sail])

Poland, Netherlands, Czechia, France, Spain, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Progressive Pulmonary Fibrosis Ppf trials by city

Progressive Pulmonary Fibrosis Ppf in Toronto Progressive Pulmonary Fibrosis Ppf in Vancouver Progressive Pulmonary Fibrosis Ppf in Montreal Progressive Pulmonary Fibrosis Ppf in Calgary Progressive Pulmonary Fibrosis Ppf in Edmonton Progressive Pulmonary Fibrosis Ppf in Ottawa Progressive Pulmonary Fibrosis Ppf in Winnipeg Progressive Pulmonary Fibrosis Ppf in Quebec City Progressive Pulmonary Fibrosis Ppf in Hamilton Progressive Pulmonary Fibrosis Ppf in Kitchener Progressive Pulmonary Fibrosis Ppf in London Progressive Pulmonary Fibrosis Ppf in Halifax Progressive Pulmonary Fibrosis Ppf in New York Progressive Pulmonary Fibrosis Ppf in Los Angeles Progressive Pulmonary Fibrosis Ppf in Chicago Progressive Pulmonary Fibrosis Ppf in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease